AEterna Zentaris Inc. (AEZS) Stock Quote

Detailed Quote for AEterna Zentaris Inc. (AEZS) 
$ 1.64   -0.06 (-3.53%) Volume: 649.14 k 3:59 PM EST Feb 10, 2012
Today 5d 1m 3m 1y more
Last Price
1.64
Change $
0.06
Change %
3.53%
Tick
N/A
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
1.70
High
1.70
Low
1.63
Prev Close
1.70
Last Trade
2/10/12
Volume
649.14 k
52 Wk Hi
2.68
52 Wk Low
1.35
Market Cap
171.93 m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
104,837,096
EPS (TTM)
-0.26
PE Ratio
N/A
Exchange
NSD
News and Media for AEterna Zentaris Inc.  (AEZS) 
Sector News | Topic News
News for AEZS
Tue, Feb 07, 2012
8:20 AM YM BioSciences and AEterna Zentaris -- Starting Strong in 2012 - Marketwire
7:30 AM Aeterna Zentaris to Present at BIO CEO Investor and RBC Capital Markets Global Healthcare Conferences in New York - Canada Newswire
7:30 AM Aeterna Zentaris to Present at BIO CEO Investor and RBC Capital Markets Global Healthcare Conferences in New York - PR Newswire
Fri, Feb 03, 2012
7:37 AM Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting - Canada Newswire
7:37 AM Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting - PR Newswire
Thu, Jan 26, 2012
7:30 AM Aeterna Zentaris: Updated Interim Phase 1 Trial Results for AEZS-108 in Prostate Cancer To Be Presented at Upcoming ASCO GCS Meeting in San Francisco - PR Newswire
7:30 AM Aeterna Zentaris: Updated Interim Phase 1 Trial Results for AEZS-108 in Prostate Cancer To Be Presented at Upcoming ASCO GCS Meeting in San Francisco - Canada Newswire
Wed, Jan 25, 2012
8:20 AM Biotechnology Industry on the Upswing -- Aeterna Zentaris and Elite Pharmaceuticals to Benefit - Marketwire
Mon, Jan 23, 2012
5:56 PM Aeterna Zentaris Announces "At-the-Market" Issuance Program - PR Newswire
5:56 PM Aeterna Zentaris Announces "At-the-Market" Issuance Program - Canada Newswire
Thu, Jan 05, 2012
8:16 AM Dendreon and AEternaZentaris Look for Stronger Performance in 2012 - Marketwire
7:30 AM Aeterna Zentaris Announces Collaboration with Ventana Medical Systems, Inc. to Develop Companion Diagnostic in Cancer for AEZS-108 - Canada Newswire
7:30 AM Aeterna Zentaris Announces Collaboration with Ventana Medical Systems, Inc. to Develop Companion Diagnostic in Cancer for AEZS-108 - PR Newswire
Tue, Jan 03, 2012
7:30 AM Aeterna Zentaris Partner, Yakult Honsha, Initiates Phase 1/2 Trial with Perifosine in Colorectal Cancer in Japan - Canada Newswire
7:30 AM Aeterna Zentaris Partner, Yakult Honsha, Initiates Phase 1/2 Trial with Perifosine in Colorectal Cancer in Japan - PR Newswire
Wed, Dec 14, 2011
9:00 AM A Change in Tides - Featured Research on Keryx Biopharmaceuticals and AEterna Zentaris Inc. (USA) - Marketwire
Tue, Dec 13, 2011
8:00 AM Aeterna Zentaris: Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting - Canada Newswire
8:00 AM Aeterna Zentaris: Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting - PR Newswire
Mon, Dec 12, 2011
8:00 AM Aeterna Zentaris: Encouraging Preclinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting - Canada Newswire
8:00 AM Aeterna Zentaris: Encouraging Preclinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting - PR Newswire
More News for AEZS >>

Tags for AEterna Zentaris Inc.

Research stocks or mutual funds related to AEterna Zentaris Inc. by keywords or tags. Find companies that have a similar focus to AEZS. The keywords below have been associated to AEZS by either user submission or electronic means.

biotech research pharmaceutical branding pharmaceutical industry strategy pharmaceutical market laboratoire recherche pharmaceutical investment prostate treatment pharmaceutical study jobs in pharmaceutical biotechnology market pharmaceutical research and development pharmaceutical supplies pharmaceutical manufacturing company pharma license biotechnologies gmp pharmaceutical clinical research pharmaceutical class pharmaceutical cro us pharmaceutical industry pharmaceutical sales clinical trials industry aeterna pharma pharmaceutical distributors pharmaceutical development vente marché pharmaceutical consultant biotech prostate support inhibitor biotechnology research Drugs le marché pharmaceutical auctions pharmaceutical industry news pharmaceutical manufacturing software etude de marché étude de marché pharmaceutical manufacturing pharmaceutical formulation biotech profile taille marché oncology pharmaceutical article pfizer pharmaceuticals contract pharmaceutical pharmaceutical industry pharmaceutical sale veterinary pharmaceutical

 

NYE - Equity | NYE - ETF | AMX - Equity | AMX - ETF | NSD - Equity | NSD - ETF
NMF - ETF | NMF - Money Market Fund | NMF - Mutual Fund | OTC - Equity | OTO - Equity | OTO - ETF | OTO - Mutual Fund
CNQ - Equity | CBO - Equity | BDM - Equity | TSX - Equity | TSX - ETF | TSX - Mutual Fund | TSV - Equity | TSV - Mutual Fund

Dow Jones Composite Index | Dow Jones Industrial Avg | Dow Jones Transportation Avg | Dow Jones Utiliy Index | NASDAQ 100
Russell 1000 | Russell 2000 | Russell 3000 | Russell Microcap | Russell Midcap | S&P 500 | S&P MidCap 400 | S&P/TSX 60 | S&P/TSX MidCap

Recently Added Symbols   Firms   Find Financial Advisors

Advisors by Name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

RIAs by Name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Tags: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Insiders: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

All information displayed and available herein is on an "as is", "as available" basis and neither InvestorPoint.com nor any of its underlying service providers, information providers, licensors, employees, distributors or agents make any representations as to the suitability of our service or the materials for any purpose. The information is not intended for trading purposes or advice. We specifically disclaim any representations or warranties, express or implied, including, without limitation, any representations or warranties of merchantability or fitness for a particular purpose. InvestorPoint.com is not an investment adviser. We do not: (a) give investment advice, (b) advocate the purchase or sale of any security or investment and (c) provide, endorse or review any information or data contained herein. We do not guarantee the accuracy of the information and data supplied by information providers. We are not liable or responsible for the quality, accuracy or reliability of this information. You should always seek the assistance of a professional for investment advice.

Copyright © 2010 InvestorPoint.com All rights reserved.